Asimov has introduced Chrysalis transposase, a proprietary genome integration enzyme engineered from the genomes of multiple butterfly species. Designed for cell line development and other biomanufacturing applications, Chrysalis supports rapid cell recovery, stable expression beyond 60 generations, and high expression across transgenes. The transposase is available for direct licensing, can be accessed within Asimov’s broader technology suite, or used through the company’s cell line development services.